Search for: "Thomas v. Pfizer Inc" Results 41 - 44 of 44
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
10 Jan 2022, 4:01 pm by INFORRM
The incident followed the publication of a peer-review article that questioned the integrity and regulatory oversight issues surrounding Pfizer’s phase III Covid-19 vaccine trial. [read post]
2 May 2008, 7:00 am
: (Patent Baristas), US: How to avoid a permanent injunction: the lessons of Amgen v Hoffman-LaRoche: (Patent Docs), US: Jarvik Heart’s PTE request based on PMA shell/module submission dates flatlines; ruling on initiation of PTE ‘review period’ mirrors FDA policy for ‘fast track’ products: (FDA Law Blog) Pharma & Biotech - Products Kytril (Granisetron) – Exclusivity ‘parking’ still… [read post]
5 Sep 2008, 11:01 pm
& Ors v Deisel Spa and Case C-302/08 Zino Davidoff SA v Bendesfinanzdirektion Sudost: (Class 46), EPO Boards of Appeal finds that when a fax is transmitted and an ‘OK’ is noted by the sender, this is evidence that the transmission was successful: (IPKat), Professor Hugenholtz slams European Commission for ignoring evidence on copyright extension: (Techdirt)   Germany Federal Patent Court publishes guidelines on colour trade mark Signal Yellow:… [read post]
13 Jul 2021, 10:58 am by Simon Lester
In the United States (US), as for most developed countries,[6] trade policy and IP standards have consistently been linked, a pattern which can (at least partially) be traced back to extensive lobbying by senior management at US-based technology and pharmaceutical firms.[7] For example, since at least the 1980s, Pfizer Inc. has been involved in mobilizing other US firms and stakeholders to lobby US policymakers on the issue of international IP protection. [read post]